Status:
COMPLETED
Hepatitis C Treatment in Probation and Parole Office
Lead Sponsor:
Jens Rosenau
Collaborating Sponsors:
AbbVie
Conditions:
Hepatitis C
HCV
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
This prospective cohort study compares aims to determine the efficacy and effectiveness of telemedicine-supported on-site linkage to care and treatment in a community probation and parole office (P\&P...
Eligibility Criteria
Inclusion
- Clients who will be supervised in the probation and parole office for at least 5 months
- History of hepatitis C
- Able to obtain health insurance
- Capacity to provide written, informed consent
- Life expectancy \>1 year
Exclusion
- Negative HCV RNA
- Pregnant or breast-feeding
- HIV or HBV co-infection
- Liver cirrhosis with Child-Turcotte-Pugh score 6 or greater at baseline lab work
- Subjects with impaired capacity to provide informed consent
Key Trial Info
Start Date :
August 23 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2024
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT05413785
Start Date
August 23 2022
End Date
May 31 2024
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kentucky
Lexington, Kentucky, United States, 40536